From infancy to adolescence: Fifteen years of continuous treatment with hydroxyurea in sickle cell anemia

Medicine (United States)

Volumn 93, Issue 28, 2014, Pages e215-

  Hankins, Jane S ^a   Aygun, Banu ^b   Nottage, Kerri ^a   Thornburg, Courtney ^c   Smeltzer, Matthew P ^a   Ware, Russell E ^d   Wang, Winfred C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Northwell Health   (United States)

^c DUKE UNIVERSITY   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; LACTATE DEHYDROGENASE; ANTISICKLING AGENT; HEMOGLOBIN;

ACUTE CHEST SYNDROME; ADOLESCENT; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; LONG TERM CARE; MALE; MAXIMUM TOLERATED DOSE; MEAN CORPUSCULAR VOLUME; MEDICATION COMPLIANCE; MICROALBUMINURIA; NEPHROTOXICITY; NEUROIMAGING; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PAIN; PATIENT COMPLIANCE; RETICULOCYTE COUNT; RETICULOCYTOPENIA; SICKLE CELL ANEMIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; ANEMIA, SICKLE CELL; BLOOD; CHILD; CONTROLLED STUDY; DOSE RESPONSE; FORECASTING; INFANT; METABOLISM; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HEMOGLOBINS; HUMANS; HYDROXYUREA; INFANT; LEUKOCYTE COUNT; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84920198857     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000215     Document Type: Article

References (20)

1. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984; 74: 652-656.
2. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995; 332: 1317-1322.
3. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011; 377: 1663-1672.
4. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010; 85: 403-408.
5. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010; 115: 2354-2363.
6. Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001; 139: 790-796.
7. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005; 106: 2269-2275.
8. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004; 103: 2039-2045.
9. DeMontalembert M, Belloy M, Bernaudin F, et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol. 1997; 19: 313-318.
10. Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011; 86: 273-277.
11. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312: 1033-1048.
12. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010; 115: 5300-5311.
13. Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med. 1984; 311: 7-12.
14. McGann PT, Flanagan JM, Howard TA, et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer. 2012; 59: 254-257.
15. McGann PT, Howard TA, Flanagan JM, et al. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011; 154: 134-140.
16. Khayat AS, Antunes LM, Guimaraes AC, et al. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea. Clin Exp Med. 2006; 6: 33-37.
17. Maluf S, Pra D, Friedrisch JR, et al. Length of treatment and dose as determinants of mutagenicity in sickle cell disease patients treated with hydroxyurea. Environ Toxicol Pharmacol. 2009; 27: 26-29.
18. Brown AK, Sleeper LA, Miller ST, et al. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch Pediatr Adolesc Med. 1994; 148: 796-804.
19. Hayes RJ, Beckford M, Grandison Y, et al. The haematology of steady state homozygous sickle cell disease: frequency distributions, variation with age and sex, longitudinal observations. Br J Haematol. 1985; 59: 369-382.
20. Davis LR. Changing blood picture in sickle-cell anaemia from shortly after birth to adolescence. J Clin Pathol. 1976; 29: 898-901.